Kips Bay Medical Announces FDA Approval of Additional US Study Patients

MINNEAPOLIS--(BUSINESS WIRE)--Kips Bay Medical, Inc. (NASDAQ:KIPS) along with Manny Villafaña, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration (“FDA”) has granted approval for additional US patients to be enrolled in Kips Bay Medical’s “eMESH I” clinical feasibility trial of its eSVS Mesh.
MORE ON THIS TOPIC